THE TGA has advised that
Octapharma Australia Pty Ltd has
agreed to a “precautionary
voluntary recall” of all batches of
Octagam intrevenous
immunoglobulin solutions from the
Australian market.
The move is due to safety
concerns regarding an increased
incidence of thromboembolic
complications associated with the
use of the product in Europe and
the USA, the TGA said.
Octagam is used in the
management of primary and
secondary immunodeficiency, as
well as a number of other
haematological, immunological
and neurological disorders.
At this stage there is no evidence
of an increase in the number of
serious adverse events associated
with the product in Australia.
The TGA said there are adequate
supplies of alternative products,
and it’s not anticipated that the
recall will lead to any shortage of
supply.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Sep 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.